Short Term Trading Week Starting: 8th May, page-106

STTCOMP PYC, FA Long

(ASX: PHLOGICA LTD: PYC )
SP: 4.5c
MC: $93.57Million
Cash: $7,080,000 Million
www.phylogica.com

Phylogica is developing next generation intracellular biological therapeutics, including its own preclinical oncology payloads, using its proprietary best-in-class cell Functional Penetrating Phylomers® (FPPs), with quantifiably demonstrable superior endosomal escape. Phylogica’s FPPs are also being used in a number of external collaborations in modular combination with a wide range of biologic payloads developed by partners for a range of diverse disease targets. These technologies are derived from Phylogica’s Phylomer® peptide libraries.

The quality of Phylomer libraries has been validated through partnerships with major pharmaceutical companies that include Genentech, MedImmune, Pfizer and Janssen Biotech (the pharmaceutical division of Johnson & Johnson) and Roche. Phylogica offers access to its intracellular delivery technology for diverse protein/nucleic acid cargoes.
The Company has a strong and broad intellectual property portfolio around its Phylomer peptide libraries and associated technology including its proprietary technology for more efficient intracellular delivery of biologics.
Phylogica originated from a collaboration between the Telethon Institute for Child Health Research (Perth, Western Australia) and the Fox Chase Cancer Centre (Philadelphia, USA), and was spun out in 2001. The Company listed on the Australian Stock Exchange (ASXYC) in March 2005.
Phylogica is headquartered in Perth, Australia.

In January, Phylogica presented at the Bioscience Showcase in San Francisco (which was held alongside the JP Morgan Healthcare Conference) and also undertook a number of individual meetings with potential partners and collaborators. In addition to the discussions and non-disclosure agreements (NDAs) established in previous quarters, this has exposed more potential partners to Phylogica’s technology.

Genentech – Antimicrobial collaboration moves into next stage
 Following the exclusivity extension with US$2m milestone payment received from Genentech, which we announced last quarter, we have begun work with Genentech on the next stages of the research program to discover novel antibiotics utilizing Phylogica’s Phylomer® drug discovery platform, including our proprietary cell penetrating peptide discovery technology

Brunel University London – new iMyc in-vitro data in additional tumour type
 Early in vitro data has shown a very strong reduction in viability of predominately N-myc overexpressing neuroblastoma cells with administration of iMyc constructs (virally expressed). This data is promising as it further validates the potential iMyc across a broad number of tumour types, and supports the new data we have generated on selectivity, outlined in Section 2 above.

Murdoch University – oligonucleotide delivery collaboration progressing
 Last quarter, we reported that preliminary IV animal experiments showed evidence of efficacy and low-toxicity in the delivery of exon-skipping oligonucleotides in models of both Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA) to muscles in a range of locations (including cardiac, diaphragm and tibia). Further animal experiments and analysis are underway to reinforce the evidence of lower toxicity of FPPs versus other CPPs.

Dana Farber – STAT5 and YB1 programs advancing with further in-vitro data
 Our collaboration with Dana Farber using our proprietary Phylomer oncology payloads continues - with viral expression of constructs being used to generate in vitro evidence for specific effects of some of our iSTATs on STAT5 but not the related STAT3 control. The magnitude of the effect is significant with prolactin induction (which induces STAT5) but not IL16 (which induces STAT3). Inhibitory effects of the iSTATs are seen on MOL14 (AML) cells. With iYB1, significant effects on viability and MYC expression in MOL14 (AML) cells and HCT116 colon cancer cells has been seen.

Phoremost – strong phenotypic screen hits obtained using Phylomers on key cancer pathways
 Recent Phoremost screens have included screens against the undruggable KRAS and YAP cancer pathways. For these screens, several strong hits have been obtained in primary screens of 5-million Phylomer (PROTEINi) sequences. A reasonable subset of these have been confirmed in secondary assays and are now moving through a proprietary process to identify their cellular targets; as are hits from other previous screens

Any material advancements relating to the abovementioned collorobative partnerships will have the potential to change the share price

Please DYOR as this is not a buy or sell recommendation
Cheers
GF